Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33) - Wikidata - wikimedia - TriplyDB

Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)

Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)

http://www.wikidata.org/entity/Q34264359

about

Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.Sitagliptin for Type 2 diabetes: a 2015 update.

P2860

Q33835897-057272AB-9E64-4EED-B233-1288943017A3 Q36315963-94896397-3540-41C7-AFF8-7068C7AB915E Q36989711-96C99360-7C31-4155-A73D-C43EBCEFE924 Q38497683-7E6DC647-BB54-476C-9899-4A55F37EA114

P2860

Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)

http://www.wikidata.org/entity/Q34264359

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Liraglutide Versus Sitagliptin ...... l Antidiabetic Drugs (JDDM 33)

@ast

Liraglutide Versus Sitagliptin ...... l Antidiabetic Drugs (JDDM 33)

@en

Liraglutide Versus Sitagliptin ...... l Antidiabetic Drugs (JDDM 33)

@nl

type

label

Liraglutide Versus Sitagliptin ...... l Antidiabetic Drugs (JDDM 33)

@ast

Liraglutide Versus Sitagliptin ...... l Antidiabetic Drugs (JDDM 33)

@en

Liraglutide Versus Sitagliptin ...... l Antidiabetic Drugs (JDDM 33)

@nl

prefLabel

Liraglutide Versus Sitagliptin ...... l Antidiabetic Drugs (JDDM 33)

@ast

Liraglutide Versus Sitagliptin ...... l Antidiabetic Drugs (JDDM 33)

@en

Liraglutide Versus Sitagliptin ...... l Antidiabetic Drugs (JDDM 33)

@nl

P1433

Q34264359-2B7AFF73-98D3-446B-8453-4B1DAAC07924

P1476

Q34264359-51768036-A86B-419B-89CF-4FA9B572F36A

P2093

Q34264359-029F37A2-2B3C-4AD5-8212-3BED1521F0B0

Q34264359-0C373492-2262-440A-AE91-31B72BD707D5

Q34264359-372DDA5B-CBAE-4752-99B9-8EB861326841

Q34264359-3A99C26D-C264-4CFB-B259-56B4C774B2A1

Q34264359-56C638EC-DE8E-4D0C-974F-2A451A402454

Q34264359-6EE778A9-66C5-40F9-A078-18626C50A513

Q34264359-967C928A-7310-47F1-94A9-1ACB57F2E28C

Q34264359-AD31E1BA-32BE-422C-BAF2-CD109CE54DAA

P2860

Q34264359-0026FA1A-33F4-4F5C-87B4-5E7B2F7D8523

Q34264359-15F4E1DD-F44A-4E2E-9738-E4FEBECCC0C8

Q34264359-183C0260-61B3-4483-811B-BDC21D85DB99

Q34264359-1BEABCAE-AEDA-4501-85FB-EE3900B40D5A

Q34264359-29590A64-4B8F-4E83-A9AB-FDDC7216F681

Q34264359-2D8C2696-A7DF-4917-9C2F-6602A7ADBD8C

Q34264359-450747DC-23C5-483E-BD66-727B936E57B0

Q34264359-5BD71252-C009-467F-A855-FD5C996DF37D

Q34264359-605242BF-3B01-45F0-9756-4F8B898CEA47

Q34264359-6B7C1C51-C509-4E5D-96A8-BDDF90B3C36E

P304

Q34264359-3311B922-6FD5-4F53-BC3E-F612A2BB783B

P31

Q34264359-0FCFC306-E12C-48F1-905C-277F5100AA12

P356

Q34264359-96E0A88C-C1D3-4129-A08D-7406B12D3FBC

P478

Q34264359-3A26B052-22CF-4AF8-889E-868EEC726B4D

P577

Q34264359-28E369F3-FB01-4798-B959-3B2568D4D8B7

P698

Q34264359-5EDFEC15-BB26-41F9-93B2-E8597405E51E

P921

Q34264359-0565304F-9050-4710-96D3-10D49CE00EAE

Q34264359-9999BEB4-685D-45FA-9263-78A3D36F01FB

P932

Q34264359-45EC4FB9-5C42-4BA2-98E6-F91204E9A3C8

P356

P1433

Japanese clinical medicine

P1476

Liraglutide Versus Sitagliptin ...... l Antidiabetic Drugs (JDDM 33)

@en

P2093

Atsunori Kashiwagi

http://www.w3.org/2001/XMLSchema#string

Gendai Lee

http://www.w3.org/2001/XMLSchema#string

Hiroki Yokoyama

http://www.w3.org/2001/XMLSchema#string

Hiroshi Takamura

http://www.w3.org/2001/XMLSchema#string

Kohei Yamaguchi

http://www.w3.org/2001/XMLSchema#string

Koichi Hirao

http://www.w3.org/2001/XMLSchema#string

Mariko Oishi

http://www.w3.org/2001/XMLSchema#string

Noriharu Yagi

http://www.w3.org/2001/XMLSchema#string

P2860

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Desensitization of insulin secretion.

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

Responsiveness of the Problem Areas In Diabetes (PAID) questionnaire.

Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference.

The place of sulfonylureas in the therapy for type 2 diabetes mellitus.

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

P304

33-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4137/JCM.S16585

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25288908

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

multicenter trial

P932

4179438

http://www.w3.org/2001/XMLSchema#string